AI Multitask Model for HCC Treatment

Sun Yat-sen University7,000 enrolled

Overview

We will integrate multi-modal cardiac data via an AI multitask framework to develop and validate concurrent models for liver function, treatment prognosis, and microvascular invasion (MVI) prediction in hepatocellular carcinoma. The resulting tool will be prospectively deployed to guide personalized surgical, TACE, and systemic therapy decisions.

Study Type

OBSERVATIONAL

Enrollment

7,000

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

Comprehensive treatmentOTHER

Comprehensive HCC therapies include liver resection, TACE, HAIC, targeted therapy, immunotherapy and radiotherapy

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. age 18-75 years; 2. HCC diagnosed according to the European Association for the Study of the Liver/American Association for the Study of Liver Diseases criteria) 3. Eastern Cooperative Oncology Group performance status \< 2; 4. Child-Pugh class A or B liver function; Exclusion Criteria: 1. HCC combined with other malignancies; 2. missing image data during perioperative period; 3. lost to follow-up \> 12 months.

Locations (1)

Unnamed facility

Guangzhou, Guangdong, China

Outcomes

Primary Outcomes

Overall Survival

from diagnosis of HCC to death or last follow-up

Time frame: 60 months

Secondary Outcomes

Progression-free survival

from diagnosis of HCC to disease progression or last follow-up

Time frame: 60 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.